Abstract
In the March, 2010, issue of The Lancet Oncology, Thomas and colleagues1 describe the safety and efficacy of denosumab in patients with recurrent or unresectable giant-cell tumour (GCT) of bone. From a surgeon's point of view, GCT often requires amputating surgery, and recurrences do occur; therefore, denosumab is a promising systemic treatment option for GCT.2 However, the follow-up of patients in the trial by Thomas and colleagues might not have been adequate to document safety.2
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
